PPD Awarded NIH Contract for HIV Research

Pharmaceutical Product Development, LLC (PPD) has secured the fifth renewal of its long-standing contract with the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The original contract dates back to 1990, and this renewal will extend the relationship until 2024.

The renewed contract covers support for research related to HIV or HIV co-infections that includes monitoring therapeutic trials, prevention trials and vaccines work. PPD also predicts risks to clinical trial participant safety and data integrity based on measures of site performance and other known risk factors.

"The extension of this contract will allow PPD to provide important comprehensive clinical site and study monitoring services to the NIH in some of the most pivotal and exciting directions in AIDS research," said William Sharbaugh, chief operating officer of PPD. "We are privileged to continue our collaborative relationship with the NIH, leveraging our considerable resources as one of the world’s largest CROs, while capitalizing on our in-depth knowledge of infectious diseases."